The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Finkel, Patrick ^a,b   Frey, Benjamin ^a   Mayer, Friederike ^a   Bösl, Karina ^a   Werthmöller, Nina ^a   Mackensen, Andreas ^a   Gaipl, Udo S ^a   Ullrich, Evelyn ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

CD8+ T cells; hyperthermia; immunogenic cell death; in situ immunization; melanoma; NK cells; radiotherapy

Indexed keywords

CD11 ANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; GROWTH RETARDATION; HYPERTHERMIA; IMMUNIZATION; IMMUNOGENICITY; IONIZING RADIATION; LYMPH NODE; MELANOMA B16; MOUSE; NATURAL KILLER T CELL; NECROSIS; NONHUMAN; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84974822460     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1101206     Document Type: Article

References (80)

1. D.Hanahan, R.A.Weinberg. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; 10.1016/j.cell.2011.02.013
2. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Ann Rev Immunol 2013; 31:51-72; PMID:23157435; 10.1146/annurev-immunol-032712-100008
3. S.Van Cruchten, W.Van Den Broeck. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anatomia Histologia Embryologia 2002; 31:214-23; PMID:12196263; 10.1046/j.1439-0264.2002.00398.x
4. L.Vande Walle, M.Lamkanfi. Inflammasomes: caspase-1-activating platforms with critical roles in host defense. Front Microbiol 2011; 2:3; PMID:21687402; 10.3389/fmicb.2011.00003
5. S.Chera, W.Buzgariu, L.Ghila, B.Galliot. Autophagy in Hydra: a response to starvation and stress in early animal evolution. Biochimica Et Biophysica Acta 2009; 1793:1432-43; PMID:19362111; 10.1016/j.bbamcr.2009.03.010
6. A.Kaczmarek, P.Vandenabeele, D.V.Krysko. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38:209-23; PMID:23438821; 10.1016/j.immuni.2013.02.003
7. C.Schorn, C.Janko, M.Latzko, R.Chaurio, G.Schett, M.Herrmann. Monosodium urate crystals induce extracellular DNA traps in neutrophils, eosinophils, and basophils but not in mononuclear cells. Front Immunol 2012; 3:277; PMID:22969769; 10.3389/fimmu.2012.00277
8. L.Zitvogel, D.Hannani, L.Aymeric, O.Kepp, I.Martins, G.Kroemer. Antitumoral immunization during cancer chemotherapy. Bull Acad Natl Med 2012; 196:1075-86; PMID:23596856
9. J.Honeychurch, C.Dive, T.M.Illidge. Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. Oncoimmunol 2013; 2:e24501; PMID:23894711; 10.4161/onci.24501
10. H.Inoue, K.Tani. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21:39-49; PMID:23832118; 10.1038/cdd.2013.84
11. B.Frey, Y.Rubner, L.Kulzer, N.Werthmoller, E.M.Weiss, R.Fietkau, U.S.Gaipl. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 2014; 63:29-36; PMID:24052136; 10.1007/s00262-013-1474-y
12. S.M.Tan, M.Kapp, C.Flechsig, K.Kapp, J.E.Rachor, M.Eyrich, J.Loeffler, H.Einsele, G.U.Grigoleit. Stimulating surface molecules, Th1-polarizing cytokines, proven trafficking–a new protocol for the generation of clinical-grade dendritic cells. Cytotherapy 2013; 15:492-506; PMID:23480952; 10.1016/j.jcyt.2012.12.002
13. G.Multhoff, C.Botzler, M.Wiesnet, E.Muller, T.Meier, W.Wilmanns, R.D.Issels. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer J Int Du Cancer 1995; 61:272-9; PMID:7705958; 10.1002/ijc.2910610222
14. M.Gehrmann, J.Marienhagen, H.Eichholtz-Wirth, E.Fritz, J.Ellwart, M.Jaattela, T.Zilch, G.Multhoff. Dual function of membrane-bound heat shock protein 70 (Hsp70), Bag-4, and Hsp40: protection against radiation-induced effects and target structure for natural killer cells. Cell Death Differ 2005; 12:38-51; PMID:15592361; 10.1038/sj.cdd.4401510
15. E.Schmitt, M.Gehrmann, M.Brunet, G.Multhoff, C.Garrido. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukocyte Biol 2007; 81:15-27; PMID:16931602; 10.1189/jlb.0306167
16. G.Delaney, S.Jacob, C.Featherstone, M.Barton. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104:1129-37; PMID:16080176; 10.1002/cncr.21324
17. H.Wang, K.N.Yu, J.Hou, Q.Liu, W.Han. Radiation-induced bystander effect: Early process and rapid assessment. Cancer Lett 2015; 356:137-44; PMID:24139967; 10.1016/j.canlet.2013.09.031
18. U.S.Gaipl, G.Multhoff, H.Scheithauer, K.Lauber, S.Hehlgans, B.Frey, F.Rodel. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunother 2014; 6:597-610; PMID:24896628; 10.2217/imt.14.38
19. S.Demaria, B.Ng, M.L.Devitt, J.S.Babb, N.Kawashima, L.Liebes, S.C.Formenti. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58:862-70; PMID:14967443; 10.1016/j.ijrobp.2003.09.012
20. E.B.Golden, A.Chhabra, A.Chachoua, S.Adams, M.Donach, M.Fenton-Kerimian, K.Friedman, F.Ponzo, J.S.Babb, J.Goldberg et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 2015; 16:795-803; PMID:26095785; 10.1016/S1470-2045(15)00054-6
21. M.A.Postow, M.K.Callahan, C.A.Barker, Y.Yamada, J.Yuan, S.Kitano, Z.Mu, T.Rasalan, M.Adamow, E.Ritter et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Eng J Med 2012; 366:925-31; PMID:22397654; 10.1056/NEJM-oa1112824
22. S.R.Gameiro, M.L.Jammeh, M.M.Wattenberg, K.Y.Tsang, S.Ferrone, J.W.Hodge. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014; 5:403-16; PMID:24480782; 10.18632/oncotarget.1719
23. J.W.Hodge, A.Ardiani, B.Farsaci, A.R.Kwilas, S.R.Gameiro. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Sem Oncol 2012; 39:323-39; PMID:22595055; 10.1053/j.semin-oncol.2012.02.006
24. E.B.Golden, D.Frances, I.Pellicciotta, S.Demaria, M.Helen Barcellos-Hoff, S.C.Formenti. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunol 2014; 3:e28518; PMID:25071979; 10.4161/onci.28518
25. N.Bloy, J.Pol, G.Manic, I.Vitale, A.Eggermont, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunol 2014; 3:e954929; PMID:25941606; 10.4161/21624011.2014.954929
26. J.van der Zee. Heating the patient: a promising approach? Ann Oncol 2002; 13:1173-84; PMID:12181239; 10.1093/annonc/mdf280
27. P.M.Krawczyk, B.Eppink, J.Essers, J.Stap, H.Rodermond, H.Odijk, A.Zelensky, C.van Bree, L.J.Stalpers, M.R.Buist et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011; 108:9851-6; PMID:21555554; 10.1073/pnas.1101053108
28. N.R.Datta, S.G.Ordonez, U.S.Gaipl, M.M.Paulides, H.Crezee, J.Gellermann, D.Marder, E.Puric, S.Bodis. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. Cancer Treatment Rev 2015; 41(9):742-53; PMID:26051911; 10.1016/j.ctrv.2015.05.009
29. B.Frey, E.M.Weiss, Y.Rubner, R.Wunderlich, O.J.Ott, R.Sauer, R.Fietkau, U.S.Gaipl. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia 2012; 28:528-42; PMID:22690925; 10.3109/02656736.2012.677933
30. B.E.Dayanc, S.H.Beachy, J.R.Ostberg, E.A.Repasky. Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J hyperthermia 2008; 24:41-56; PMID:18214768; 10.1080/02656730701858297
31. I.Knippertz, M.F.Stein, J.Dorrie, N.Schaft, I.Muller, A.Deinzer, A.Steinkasserer, D.M.Nettelbeck. Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies. Int J Hyperther 2011; 27:591-603; PMID:21846195; 10.3109/02656736.2011.589234
32. P.Schildkopf, B.Frey, O.J.Ott, Y.Rubner, G.Multhoff, R.Sauer, R.Fietkau, U.S.Gaipl. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol 2011; 101:109-15; PMID:21704416; 10.1016/j.radonc.2011.05.056
33. S.Triantopoulou, E.Efstathopoulos, K.Platoni, N.Uzunoglou, N.Kelekis, V.Kouloulias. Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters. Clin Transl Oncol 2013; 15:95-105; PMID:23180345; 10.1007/s12094-012-0947-3
34. N.Werthmoller, B.Frey, R.Wunderlich, R.Fietkau, U.S.Gaipl. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis 2015; 6:e1761; PMID:25973681; 10.1038/cddis.2015.129
35. B.Homet Moreno, G.Parisi, L.Robert, A.Ribas. Anti-PD-1 Therapy in Melanoma. Sem Oncol 2015; 42:466-73; PMID:25965365; 10.1053/j.seminoncol.2015.02.008
36. S.H.Ko, T.Ueno, Y.Yoshimoto, J.S.Yoo, O.I.Abdel-Wahab, Z.Abdel-Wahab, E.Chu, S.K.Pruitt, H.S.Friedman, M.W.Dewhirst et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006; 12:289-97; PMID:16397054; 10.1158/1078-0432.CCR-05-0210
37. J.Y.Lim, D.G.Brockstedt, E.M.Lord, S.A.Gerber. Radiation therapy combined with -based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncoimmunol 2014; 3:e29028; PMID:25083327; 10.4161/onci.29028
38. R.Kiessling, E.Klein, H.Wigzell. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5:112-7; PMID:1234049; 10.1002/eji.1830050208
39. K.Karre, H.G.Ljunggren, G.Piontek, R.Kiessling. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675-8; PMID:3951539; 10.1038/319675a0
40. E.Ullrich, J.Koch, A.Cerwenka, A.Steinle. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunol 2013; 2:e26097; PMID:24353908; 10.4161/onci.26097
41. E.Vivier, D.H.Raulet, A.Moretta, M.A.Caligiuri, L.Zitvogel, L.L.Lanier, W.M.Yokoyama, S.Ugolini. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; 10.1126/science.1198687
42. Y.Hayakawa, N.D.Huntington, S.L.Nutt, M.J.Smyth. Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214:47-55; PMID:17100875; 10.1111/j.1600-065X.2006.00454.x
43. L.Chiossone, J.Chaix, N.Fuseri, C.Roth, E.Vivier, T.Walzer. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009; 113:5488-96; PMID:19234143; 10.1182/blood-2008-10-187179
44. J.P.Di Santo. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24:257-86; PMID:16551250; 10.1146/annurev.immunol.24.021605.090700
45. K.Meinhardt, I.Kroeger, R.Bauer, F.Ganss, I.Ovsiy, J.Rothamer, M.Buttner, I.Atreya, M.Waldner, M.Bittrich et al. Identification and characterization of the specific murine NK cell subset supporting graft–leukemia- and reducing graft–host-effects. Oncoimmunol 2015; 4:e981483; PMID:25949862; 10.4161/21624-02X.2014.981483
46. Y.Hayakawa, S.V.Watt, K.Takeda, M.J.Smyth. Distinct receptor repertoire formation in mouse NK cell subsets regulated by MHC class I expression. J Leukocyte Biol 2008; 83:106-11; PMID:17940219; 10.1189/jlb.0707496
47. A.Martin-Fontecha, L.L.Thomsen, S.Brett, C.Gerard, M.Lipp, A.Lanzavecchia, F.Sallusto. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5:1260-5; PMID:15531883; 10.1038/ni1138
48. M.J.Smyth, Y.Hayakawa, K.Takeda, H.Yagita. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850-61; PMID:12415255; 10.1038/nrc928
49. T.Osada, T.Clay, A.Hobeika, H.K.Lyerly, M.A.Morse. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 2006; 55:1122-31; PMID:16273350; 10.1007/s00262-005-0089-3
50. K.Soderquest, T.Walzer, B.Zafirova, L.S.Klavinskis, B.Polic, E.Vivier, G.M.Lord, A.Martin-Fontecha. Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses. J Immunol 2011; 186:3304-8; PMID:21307295; 10.4049/jimmunol.1004122
51. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunol 2014; 3:e955691; PMID:25941621; 10.4161/21624011.2014.955691
52. T.Hehr, P.Wust, M.Bamberg, W.Budach. Current and potential role of thermoradiotherapy for solid tumours. Onkologie 2003; 26:295-302; PMID:12845217; ; 10.1159/0000-71628
53. Y.Rubner, R.Wunderlich, P.F.Ruhle, L.Kulzer, N.Werthmoller, B.Frey, E.M.Weiss, L.Keilholz, R.Fietkau, U.S.Gaipl. How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol 2012; 2:75; PMID:22848871; 10.3389/fonc.2012.00075
54. M.Aris, M.M.Barrio. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015; 6:46; PMID:25709607; 10.3389/fimmu.2015.00046
55. C.R.Lindsay, P.Spiliopoulou, A.Waterston. Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Adv Med Oncol 2015; 7:107-21; PMID:25755683; 10.1177/1758834014566619
56. J.Ozao-Choy, D.J.Lee, M.B.Faries. Melanoma vaccines: mixed past, promising future. Surg Clin N Am 2014; 94:1017-30,; PMID:25245965; 10.1016/j.suc.2014.07.005
57. S.A.Rosenberg, N.P.Restifo. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348:62-8; PMID:25838374; 10.1126/science.aaa4967
58. K.Lauber, E.Bohn, S.M.Krober, Y.J.Xiao, S.G.Blumenthal, R.K.Lindemann, P.Marini, C.Wiedig, A.Zobywalski, S.Baksh et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003; 113:717-30; PMID:12809603; 10.1016/S0092-8674(03)00422-7
59. P.Scaffidi, T.Misteli, M.E.Bianchi. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418:191-5; PMID:12110890; 10.1038/nature00858
60. L.Apetoh, F.Ghiringhelli, A.Tesniere, M.Obeid, C.Ortiz, A.Criollo, G.Mignot, M.C.Maiuri, E.Ullrich, P.Saulnier et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; 10.1038/nm1622
61. D.Messmer, H.Yang, G.Telusma, F.Knoll, J.Li, B.Messmer, K.J.Tracey, N.Chiorazzi. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173:307-13; 10.4049/jimmunol.173.1.307
62. R.A.DeMarco, M.P.Fink, M.T.Lotze. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 2005; 42:433-44; PMID:15607795; 10.1016/j.molimm.2004.07.023
63. J.Radons, G.Multhoff. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exercise Immunol Rev 2005; 11:17-33; PMID:16385841
64. L.Elsner, V.Muppala, M.Gehrmann, J.Lozano, D.Malzahn, H.Bickeboller, E.Brunner, M.Zientkowska, T.Herrmann, L.Walter et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 2007; 179:5523-33; PMID:17911639; 10.4049/jimmunol.179.8.5523
65. I.E.Dumitriu, M.E.Bianchi, M.Bacci, A.A.Manfredi, P.Rovere-Querini. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukocyte Biol 2007; 81:84-91; PMID:17035340; 10.1189/jlb.0306171
66. L.Cottone, A.Capobianco, C.Gualteroni, C.Perrotta, M.E.Bianchi, P.Rovere-Querini, A.A.Manfredi. 5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells. Int J Cancer J Int Du Cancer 2015; 136:1381-9; PMID:25098891; 10.1002/ijc.29125
67. A.Capobianco, A.A.Manfredi, A.Monno, P.Rovere-Querini, C.Rugarli. Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. J Immunother 2008; 31:458-65; PMID:18463539; 10.1097/CJI.0b013e318174a512
68. Y.Hayakawa, M.J.Smyth. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006; 176:1517-24; PMID:16424180; 10.4049/jimmunol.176.3.1517
69. K.Meinhardt, I.Kroeger, A.Abendroth, S.Muller, A.Mackensen, E.Ullrich. Influence of NK cell magnetic bead isolation methods on phenotype and function of murine NK cells. J Immunol Met 2012; 378:1-10; PMID:22306357; 10.1016/j.jim.2012.01.008
70. K.Geisler, A.Reischer, I.Kroeger, B.Jacobs, K.Meinhardt, R.Bauer, B.Ryffel, A.Mackensen, E.Ullrich. Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. Oncol Rep 2014; 31:2015-20; PMID:24626639; 10.3892/or.2014.3070
71. K.Takeda, M.Nakayama, M.Sakaki, Y.Hayakawa, M.Imawari, K.Ogasawara, K.Okumura, M.J.Smyth. IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J Leukocyte Biol 2011; 90:777-85; PMID:21712396; 10.1189/jlb.0411208
72. W.Deng, B.G.Gowen, L.Zhang, L.Wang, S.Lau, A.Iannello, J.Xu, T.L.Rovis, N.Xiong, D.H.Raulet. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 2015; 348:136-9; PMID:25745066; 10.1126/science.1258867
73. T.Walzer, M.Dalod, S.H.Robbins, L.Zitvogel, E.Vivier. Natural-killer cells and dendritic cells: “l'union fait la force.” Blood 2005; 106:2252-8; PMID:15933055; 10.1182/blood-2005-03-1154
74. S.J.Dovedi, A.L.Adlard, G.Lipowska-Bhalla, C.McKenna, S.Jones, E.J.Cheadle, I.J.Stratford, E.Poon, M.Morrow, R.Stewart et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74:5458-68; PMID:25274032; 10.1158/0008-5472.CAN-14-1258
75. B.Frey, U.S.Gaipl. Radio-immunotherapy: the focused beam expands. Lancet Oncol 2015; 16:742-3; PMID:26095779; 10.1016/S1470-2045(15)00055-8
76. B.Frey, Y.Rubner, R.Wunderlich, E.M.Weiss, A.G.Pockley, R.Fietkau, U.S.Gaipl. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr Med Chem 2012; 19:1751-64; PMID:22414083; 10.2174/092986712800099811
77. R.I.Geran, N.H.Greenberg, M.M.Macdonald, B.J.Abbott. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI. Natl Cancer Inst Monograph 1977; 45:151-3; PMID:927490.
78. E.M.Weiss, S.Meister, C.Janko, N.Ebel, E.Schlucker, R.Meyer-Pittroff, R.Fietkau, M.Herrmann, U.S.Gaipl, B.Frey. High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. J Immunotoxicol 2010; 7:194-204; PMID:20205624; 10.3109/15476911003657414
79. D.R.Parks, M.Roederer, W.A.Moore. A new “Logicle” display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. Cytometry Part A 2006; 69:541-51; PMID:16604519; 10.1002/cyto.a.20258
80. J.W.Tung, D.R.Parks, W.A.Moore, L.A.Herzenberg, L.A.Herzenberg. Identification of B-cell subsets: an exposition of 11-color (Hi-D) FACS methods. Met Mol Biol 2004; 271:37-58; PMID:15146111; 10.1385/1-59259-796-3:037